Richard Lipman

The Qsymia Plan for Weight Loss: A Practical Guide to Using the New Diet Medication (eBook, ePUB)

• Format: ePub

Produktbeschreibung

So what has triggered people to think about using medications for weight loss? It is the frustrating disappointment of all kinds of weight loss plans and the fact that the medical community fails to see obesity as an illness. Often doctors believe that their obese patients simply have no will power and control and thus they hold back medications that could assist them with weight loss. Other doctors believe, frequently without vocalizing it, that dropping weight and sustaining fat loss is a hopeless situation anyway so why try? While other people associate all diet prescription drugs with phen/fen.

Over the previous few years, there has been a shift in perspective on the part of doctors and their therapy of obesity. They have seen such horrible complications: epidemics of diabetes and its complications, strokes, and coronary heart disorders that they are prepared to try various other modes of treatment. Just look at the escalating number of gastric bypass surgical procedures in the previous several years. The FDA has authorized two brand new drugs in 2013 - Qsymia and Belviq.

The first, Qsymia is readily available now with a doctor's prescription.. Qsymia is a prescription treatment that is made up of phentermine and Topamax (topiramate extended-release) that may help some obese adults or some over weight adults who also have weight-related medical conditions lose weight and keep the weight off. The phentermine is the appetite reducer and is similar to the phentermine in Adipex and Fastin that's been on the market since the mid 1970's. The Topamax has been available for a decade and is used for seizures and headaches. So Qsymia is not really newit's 2 older drugs blended in a distinctive delivery method with 4 different dosing levels that stretch over months. A titrated dose delivery system was developed to lessen the side effects.

Endocrinologist and weight loss expert Dr Richard Lipman presents the first book focusing on this newest FDA approved weight loss drug, Qsymia. Dr Lipman reviews the clinical trials of Qsymia and answers the questions whether Qsymia is for you, the side effects, the expected weight loss and how long it can be taken. He presents a simple plan for weight loss that can be successful for just about anyone.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, CY, CZ, D, DK, EW, E, FIN, F, GR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Richard Lipman MD
• Erscheinungstermin: 22. April 2013
• Englisch
• ISBN-13: 9781301755509
• Artikelnr.: 74341345

Autorenporträt

Richard L. Lipman M.D. has practiced internal medicine and endocrinology in his office in Miami, Fl for the past 30 years. As a board certified internist and board eligible endocrinologist he has treated more than 15,000 patients with weight and metabolism problems. Dr Lipman is a Charter Member of the American Association of Clinical Endocrinologists. He has treated hundreds of patients with HCG over the past two years.
Dr. Lipman received a BS degree in biochemistry and a MD in 1966 from the University of Pittsburgh. Dr. Lipman did his internship and residency in internal medicine at the University of Pittsburgh Medical Center Hospitals and a fellowship in Endocrinology at the University of Miami School of Medicine. While at the University of Miami, he authored and coauthored 15 publications in the areas of glucose and growth hormone metabolism. Dr. Lipman also spent two years at the United States Air Force School of Aerospace Medicine, where he was a staff member of the Endocrinology Division at the USAF Hospital in San Antonio, Texas. While in the Air Force, Dr. Lipman authored six publications on the effects of prolonged weightlessness on glucose and protein metabolism. Dr. Lipman is a staff member of Larkin and Cedars Hospital in Miami, a charter member of the American Association of Clinical Endocrinologists, and a member of the American Diabetes Association and the American Association of Bariatric Physicians.

He has treated more than 700 patients in his Miami, Fl office with the new Semaglutides-Ozempic and Wegovy and the even new Tirzepatides-Mounjaro and Zepbound. He relates his experience in his new book, Semaglutides: Once a Week Weight Loss Injections .